Plasma Aβ42 correlates positively with increased body fat in healthy individuals
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Obesity and overweight, well known risk factors for cardiovascular disease and type 2 diabetes, are now associated with Alzheimer's disease (AD). It remains to be determined if obesity and overweight contribute to the risk of developing AD through modulating levels of amyloid-beta (Abeta), a key molecule in AD pathogenesis. Thus, we investigated whether there were any associations between plasma Abeta levels and body mass index (BMI) or fat mass (FM) in a group of 18 healthy adults. A statistically significant correlation was found between BMI, FM, and plasma levels of Abeta42 (BMI r = 0.602, P = 0.008; FM r = 0.547, P = 0.019), the longer, more pathogenic form of Abeta, but not with plasma levels of the shorter, less pathogenic Abeta40. Although not significant, positive correlations between plasma levels of Abeta42 and levels of insulin and the inflammatory marker C-reactive protein (CRP), along with an inverse trend between plasma Abeta42 levels and levels of high density lipoprotein (HDL) were answered. These results suggest that proteins implicated in inflammation, cardiovascular disease and type 2 diabetes, which in turn are risk factors for AD, may contribute to the associations between BMI/FM and plasma Abeta42 levels. Longitudinal studies involving larger cohorts are required to determine if elevated body fat may predispose individuals to AD through increasing Abeta42 levels throughout early to late adulthood.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Black, S., Kushner, I., & Samols, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400025200 · Cited by 1,844
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 1×
“Such markers include, interleukin-1 (IL-1) [22], interleukin-6 (IL-6) [72,76], tumour necrosis factor alpha (TNF-α ) [16] and transforming growth factor-β (TGF-β ) [8,68,79].”
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 1×
“anti-inflammatory drugs on AD risk [29,48,78].”
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · cited 1×
“Plasma Aβ40 and Aβ42 levels were determined using a double antibody sandwich enzyme immunosorbent (ELISA) as previously described [49, 54].”
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196 · cited 1×
“anti-inflammatory drugs on AD risk [29,48,78].”
(1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.17.1855 · Cited by 936
Tracy, R. P., Lemaitre, R. N., Psaty, B. M., Ives, D. G., Evans, R. W., Cushman, M., Meilahn, E. N., & Kuller, L. H. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.6.1121 · Cited by 836 · cited 2×
“Elevated levels of the C-reactive protein (CRP), a sensitive and stable marker of inflammation [63], has been associated with increased body mass index (BMI; a measure of obesity), serum lipids (indicator of cardiovascular disease risk) and increased fasting glucose levels (indication of diabetes) [10,17,25,30,34,70].”
Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease
Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582
Self-citationInterleukin-6 and risk of cognitive decline: MacArthur Studies of Successful Aging
Weaver, J. D., Huang, M.-H., Albert, M., Harris, T., Rowe, J. W., & Seeman, T. E. (2002) · Neurology · doi:10.1212/wnl.59.3.371 · Cited by 536
Cook, D. G., Mendall, M. A., Whincup, P. H., Carey, I. M., Ballam, L., Morris, J. E., Miller, G. J., & Strachan, D. P. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00312-3 · Cited by 446 · cited 2×
“Elevated levels of the C-reactive protein (CRP), a sensitive and stable marker of inflammation [63], has been associated with increased body mass index (BMI; a measure of obesity), serum lipids (indicator of cardiovascular disease risk) and increased fasting glucose levels (indication of diabetes) [10,17,25,30,34,70].”
Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434
Self-citationLiao, Y.-F., Wang, B.-J., Cheng, H.-T., Kuo, L.-H., & Wolfe, M. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402034200 · Cited by 389 · cited 1×
“Some of these in-flammatory markers including IL-1 β , TNF-α and IL-6 have been shown to regulate the production of A β , particularly A β 42 [5,43,59].”
Tarkowski, E., Issa, R., Sjögren, M., Wallin, A., Blennow, K., Tarkowski, A., & Kumar, P. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00285-8 · Cited by 360 · cited 1×
“Such markers include, interleukin-1 (IL-1) [22], interleukin-6 (IL-6) [72,76], tumour necrosis factor alpha (TNF-α ) [16] and transforming growth factor-β (TGF-β ) [8,68,79].”
Ridker, P. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.028 · Cited by 290
Khaodhiar, L., Ling, P., Blackburn, G. L., & Bistrian, B. R. (2004) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607104028006410 · Cited by 243 · cited 1×
“However, as previously re-ported [21,33,61,66], we found that increased levels of BMI were strongly associated with increases in CRP levels ( r = 0 .”
Laws, S. M., Hone, E., Gandy, S., & Martins, R. N. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01615.x · Cited by 223 · cited 1×
“These risk factors appear to be exacerbated in individuals carrying the apolipoprotein E4 ( APOE ε 4 ) allele such that they have an increased risk of developing type – 2 diabetes, hypertension, hypercholestero-laemia, cardiovasculardisease and Alzheimer’s disease (reviewed in [6,42]).”
Self-citationBody Mass Index, but Not Physical Activity, Is Associated with C-Reactive Protein
RAWSON, E. S., FREEDSON, P. S., OSGANIAN, S. K., MATTHEWS, C. E., REED, G., & OCKENE, I. S. (2003) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000074565.79230.ab · Cited by 144
Increased plasma amyloid β protein 1–42 levels in Down syndrome
Mehta, P. D., Dalton, A. J., Mehta, S. P., Kim, K. S., Sersen, E. A., & Wisniewski, H. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00966-x · Cited by 108 · cited 1×
“Plasma Aβ40 and Aβ42 levels were determined using a double antibody sandwich enzyme immunosorbent (ELISA) as previously described [49, 54].”
Self-citationTrischitta, V., Brunetti, A., Chiavetta, A., Benzi, L., Papa, V., & Vigneri, R. (1989) · Diabetes · doi:10.2337/diab.38.12.1579 · Cited by 61
Mulder, M., & Terwel, D. (1998) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000022429 · Cited by 40 · cited 1×
“Furthermore, HDL has been shown to interact with A β in plasma [52,53] and can regulate A β aggregation, degradation and toxicity [9,13,57] suggesting possible mechanisms by which HDL could modify the risk of developing AD.”
Cited by
Microglial priming in neurodegenerative disease
Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127
Obesity and neuroinflammation: A pathway to cognitive impairment
Miller, A. A., & Spencer, S. J. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.04.001 · Cited by 788
Deciphering the mechanism underlying late-onset Alzheimer disease
Krstic, D., & Knuesel, I. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.236 · Cited by 457
Martins, I. J., Hone, E., Foster, J. K., Sünram-Lea, S. I., Gnjec, A., Fuller, S. J., Nolan, D., Gandy, S. E., & Martins, R. N. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001854 · Cited by 388
Self-citationGunstad, J., Lhotsky, A., Wendell, C. R., Ferrucci, L., & Zonderman, A. B. (2010) · Neuroepidemiology · doi:10.1159/000297742 · Cited by 369
Metadata
- Authors
- Balakrishnan, K., Verdile, G., Mehta, P. D., Beilby, J., Nolan, D., Galvão, D. A., Newton, R., Gandy, S. E., & Martins, R. N.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2005-12-05
- Volume
- 8
- Issue
- 3
- Pages
- 269-282
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1594033512
- Cited by
- 75
- References
- 22
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.